Biosimilars Market By Product Type (Recombinant Peptides, Glycosylated Proteins, Recombinant Non- Glycosylated Proteins, Recombinant Non- Glycosylated Proteins), By Application (Blood Disorders, Chronic And Autoimmune Diseases, Oncology, Growth Hormone Deficiency, Infectious Diseases), By Technology (Nuclear Magnetic Resonance (NMR) Technology, Western Blotting, Monoclonal Antibodies (MAB) Technology, Electrophoresis, Chromatography, Bioassay, Recombinant DNA Technology, Mass Spectrometry), By Services (Clinical Trials, Contract Research & Manufacturing Services (CRMS)), Industry Size, Growth, Share And Forecast To 2022

Published By: Brisk Insights | Published On: Apr 20, 2016

Key Findings


The global biosimilars market is expected to grow at the an CAGR of 22.6% from 2015 to 2022 and expected to reach $6.22billion by 2022.The major factors driving the market are increase in number off patented drugs and growing geriatric population leading to increasing chronic disease incidences. Patent expiration is the major driving factor of the biosimilars market. Validation and development of biosimilars with reference biologics plays a significant role in commercialization of biosimilars. Biosimilar industry is facing problems related to high cost and complexities associated with manufacturing. The average cost of biologics in unites states is $45 compared with $2 for chemical drugs.


Market Segment Insight


The market is majorly segmented on the basis of product type, application, technology and service. On the basis of product type market is segmented into Recombinant Peptides market, Recombinant Glycosylated Proteins and Recombinant Non-Glycosylated Proteins. Recombinant Non-Glycosylated Proteins dominates the global biosimilars market in the product segment. Recombinant Glycosylated Proteins is anticipated to be the fastest growing segment in this market. Global Biosimilars market can further be segmented on the basis of applications including Oncology, Blood Disorders, Infectious Diseases, Chronic, and Autoimmune Diseases and Other Applications. On the basis of technology it is bifurcated into Nuclear magnetic resonance technology, Western blotting, Monoclonal antibodies technology, Electrophoresis, Chromatography, Bioassay, Recombinant DNA technology and Mass spectrometry.


Regional Insight:


Europe is the largest market for biosimilars owing to supportive government regulations followed by Asia Pacific.
Asia Pacific region is anticipated to be the fastest growing market and accounted for 45%of total market revenue in 2013. This region is growing at a faster pace owing to presence of large population of patients, developing healthcare infrastructure and growing focus of key players on emerging Asia Pacific economies. North America is also anticipated to witness significant growth over the forecasted period. U.S. contributes 49% in the total sales of North America’s biosimilars market.


Competitive Insights

Some of the major market players are Hospira, Inc., Dr. Reddy’s Laboratories, Sandoz International GmbH, Teva Pharmaceutical Industries Ltd., Mylan, Inc., Biocon Limited and so on. New product launches, mergers & acquisitions and agreements & collaborations are the key strategies adopted by the market players to sustain in the market.

CHAP 1. METHODOLOGY & SCOPE 14
1.1. RESEARCH METHODOLOGY 14
1.2. RESEARCH SCOPE & ASSUMPTIONS 14
1.3. LIST OF DATA SOURCES 14


CHAP 2. EXECUTIVE SUMMARY 15
2.1. GLOBAL BIOSIMILARS MARKET SUMMARY & KEY BUYING CRITERIA 15
2.2. GLOBAL BIOSIMILARS MARKET OUTLOOK 15
2.3. MARKET SEGMENTATION ANALYSIS 15
2.4. MARKET SIZE AND GROWTH PROSPECTS 2012-2022 15
2.5. GLOBAL BIOSIMILARS MARKET VALUE CHAIN ANALYSIS 15
2.6. VENDOR LANDSCAPE 15


CHAP 3. GLOBAL BIOSIMILARS MARKET 16
3.1. MARKET DRIVER ANALYSIS 16
3.1.1. RISE IN NUMBER OF OFF-PATENTED DRUGS 16
3.1.2. INCREASING PRESSURE TO DECREASE HEALTHCARE EXPENDITURE 16
3.1.3. COST EFFECTIVENESS IS DRIVING DEMAND FOR BIOSIMILARS DRUGS 16
3.1.4. WIDE THERAPEUTIC APPLICATIONS 16
3.1.5. INCREASING GERIATRIC POPULATION LEADING TO GROWING CHRONIC DISORDER INCIDENCES 16
3.1.6. SUPPORTIVE GOVERNMENT INITIATIVES 16
3.2. MARKET RESTRAINT ANALYSIS 16
3.2.1. STRINGENT REGULATIONS TO RESTRICT INVESTMENT IN DEVELOPED ECONOMIES 16
3.2.2. HIGH COST AND COMPLEXITIES ASSOCIATED WITH MANUFACTURING 16
3.2.3. PATIENT SAFETY & MEDICAL EFFICACY 16
3.2.4. HUGE INVESTMENT FOR RESEARCH & DEVELOPMENT 16
3.3. KEY OPPORTUNITIES 16
3.3.1. UNTAPPED EMERGING MARKETS 16
3.3.2. OFF-PATENT BIOLOGICAL PRODUCTS LEADS TO OPPORTUNITIES FOR BIOSIMILARS 16
3.4. CHALLENGES 16
3.4.1. FLEDGLING REGULATORY FRAMEWORK 16
3.4.2. MANUFACTURING ISSUES 16


CHAP 4. INDUSTRY ANALYSIS 17
4.1. GLOBAL BIOSIMILARS MARKET– PORTER’S FIVE FORCE MODEL 17
4.2. GLOBAL BIOSIMILARS MARKET– PESTEL ANALYSIS 17
4.3. GLOBAL BIOSIMILARS MARKET– GAP ANALYSIS 17


CHAP 5. GLOBAL BIOSIMILARS MARKET BY PRODUCT TYPE 2012-2022 ($ BILLION) 18
5.1. GLOBAL BIOSIMILARS MARKET BY RECOMBINANT PEPTIDES , 2012-2022 ($ BILLION) 18
5.1.1. GLOBAL BIOSIMILARS RECOMBINANT PEPTIDES MARKET BY GLUCAGON , 2012-2022 ($ BILLION) 18
5.1.2. GLOBAL BIOSIMILARS RECOMBINANT PEPTIDES MARKET BY CALCITONIN , 2012-2022 ($ BILLION) 18
5.2. GLOBAL BIOSIMILARS MARKET BY GLYCOSYLATED PROTEINS, 2012-2022 ($ BILLION) 18
5.2.1. GLOBAL BIOSIMILARS GLYCOSYLATED PROTEINS MARKET BY ERYTHROPOIETIN (EPO), 2012-2022 ($ BILLION) 18
5.2.2. GLOBAL BIOSIMILARS GLYCOSYLATED PROTEINS MARKET BY FOLLITROPIN, 2012-2022 ($ BILLION) 18
5.2.3. GLOBAL BIOSIMILARS GLYCOSYLATED PROTEINS MARKET BY MONOCLONAL ANTIBODIES (MABS) , 2012-2022 ($ BILLION) 18
5.3. GLOBAL BIOSIMILARS MARKET BY RECOMBINANT NON- GLYCOSYLATED PROTEINS, 2012-2022 ($ BILLION) 18
5.3.1. GLOBAL BIOSIMILARS RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET BY INTERFERONS, 2012-2022 ($ BILLION) 18
5.3.2. GLOBAL BIOSIMILARS RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET BY RECOMBINANT HUMAN GROWTH HORMONE (RHGH) , 2012-2022 ($ BILLION) 18
5.3.3. GLOBAL BIOSIMILARS RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET BY GRANULOCYTE COLONY-STIMULATING FACTOR (FILGRASTIM) , 2012-2022 ($ BILLION) 18
5.3.4. GLOBAL BIOSIMILARS RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET BY INSULIN, 2012-2022 ($ BILLION) 19


CHAP 6. GLOBAL BIOSIMILARS MARKET BY APPLICATION 2012-2022 ($ BILLION) 20
6.1. GLOBAL BIOSIMILARS MARKET BY BLOOD DISORDERS , 2012-2022 ($ BILLION) 20
6.2. GLOBAL BIOSIMILARS MARKET BY CHRONIC AND AUTOIMMUNE DISEASES, 2012-2022 ($ BILLION) 20
6.3. GLOBAL BIOSIMILARS MARKET BY ONCOLOGY, 2012-2022 ($ BILLION) 20
6.4. GLOBAL BIOSIMILARS MARKET BY GROWTH HORMONE DEFICIENCY, 2012-2022 ($ BILLION) 20
6.5. GLOBAL BIOSIMILARS MARKET BY INFECTIOUS DISEASES, 2012-2022 ($ BILLION) 20
6.6. GLOBAL BIOSIMILARS MARKET BY OTHER APPLICATIONS, 2012-2022 ($ BILLION) 20


CHAP 7. GLOBAL BIOSIMILARS MARKET BY TECHNOLOGY 2012-2022 ($ BILLION) 21
7.1. GLOBAL BIOSIMILARS MARKET BY NUCLEAR MAGNETIC RESONANCE (NMR) TECHNOLOGY, 2012-2022 ($ BILLION) 21
7.2. GLOBAL BIOSIMILARS MARKET BY WESTERN BLOTTING, 2012-2022 ($ BILLION) 21
7.3. GLOBAL BIOSIMILARS MARKET BY MONOCLONAL ANTIBODIES (MAB) TECHNOLOGY, 2012-2022 ($ BILLION) 21
7.4. GLOBAL BIOSIMILARS MARKET BY ELECTROPHORESIS, 2012-2022 ($ BILLION) 21
7.5. GLOBAL BIOSIMILARS MARKET BY CHROMATOGRAPHY, 2012-2022 ($ BILLION) 21
7.6. GLOBAL BIOSIMILARS MARKET BY BIOASSAY, 2012-2022 ($ BILLION) 21
7.7. GLOBAL BIOSIMILARS MARKET BY RECOMBINANT DNA TECHNOLOGY, 2012-2022 ($ BILLION) 21
7.8. GLOBAL BIOSIMILARS MARKET BY MASS SPECTROMETRY, 2012-2022 ($ BILLION) 21


CHAP 8. GLOBAL BIOSIMILARS MARKET BY SERVICES 2012-2022 ($ BILLION) 22
8.1. GLOBAL BIOSIMILARS MARKET BY CLINICAL TRIALS, 2012-2022 ($ BILLION) 22
8.2. GLOBAL BIOSIMILARS MARKET BY CONTRACT RESEARCH & MANUFACTURING SERVICES (CRMS), 2012-2022 ($ BILLION) 22


CHAP 9. GLOBAL BIOSIMILARS MARKET, REGIONAL OUTLOOK 2012-2022 ($ BILLION) 23
9.1. GLOBAL BIOSIMILARS MARKET BY REGION 2012-2022 ($ BILLION) 23
9.2. NORTH AMERICA 23
9.2.1. NORTH AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 23
9.2.2. NORTH AMERICA MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ BILLION) 23
9.2.3. NORTH AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 23
9.2.3.1. U.S. 23
9.2.3.1.1. U.S. MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 23
9.2.3.1.2. U.S. MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 23
9.2.3.2. CANADA 23
9.2.3.2.1. CANADA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 23
9.2.3.2.2. CANADA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 23
9.3. EUROPE 23
9.3.1. EUROPE MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 23
9.3.2. EUROPE MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ BILLION) 23
9.3.3. EUROPE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 23
9.3.3.1. GERMANY 23
9.3.3.1.1. GERMANY MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 24
9.3.3.1.2. GERMANY MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 24
9.3.3.2. UK 24
9.3.3.2.1. UK MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 24
9.3.3.2.2. UK MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 24
9.3.3.3. FRANCE 24
9.3.3.3.1. FRANCE MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 24
9.3.3.3.2. FRANCE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 24
9.3.3.4. SPAIN 24
9.3.3.4.1. SPAIN MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 24
9.3.3.4.2. SPAIN MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 24
9.3.3.5. REST OF EUROPE 24
9.3.3.5.1. RUSSIA MARKET ESTIMATES AND FORECAST2012-2022($BILLION) 24
9.3.3.5.2. RUSSIA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022($BILLION) 24
9.3.3.5.3. OTHERS MARKET ESTIMATES AND FORECAST2012-2022($BILLION) 24
9.3.3.5.4. OTHERS MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022($BILLION) 24
9.4. ASIA PACIFIC 25
9.4.1. ASIA PACIFIC MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 25
9.4.2. ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ BILLION) 25
9.4.3. ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 25
9.4.3.1. CHINA 25
9.4.3.1.1. CHINA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 25
9.4.3.1.2. CHINA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 25
9.4.3.2. INDIA 25
9.4.3.2.1. INDIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 25
9.4.3.2.2. INDIA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 25
9.4.3.3. JAPAN 25
9.4.3.3.1. JAPAN MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 25
9.4.3.3.2. JAPAN MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($BILLION) 25
9.4.3.4. SOUTH KOREA 25
9.4.3.4.1. SOUTH KOREA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 25
9.4.3.4.2. SOUTH KOREA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($BILLION) 25
9.4.3.5. OTHERS 25
9.4.3.5.1. OTHER MARKET ESTIMATES AND FORECASTS 2012-2022($BILLION) 26
9.4.3.5.2. OTHER MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022($BILLION) 26
9.5. MIDDLE EAST & AFRICA 26
9.5.1. MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 26
9.5.2. MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 26
9.6. LATIN AMERICA 26
9.6.1. LATIN AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 26
9.6.2. LATIN AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 26
9.6.2.1. BRAZIL 26
9.6.2.1.1. BRAZIL MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 26
9.6.2.1.2. BRAZIL MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 26


CHAP 10. COMPETITIVE LANDSCAPE 27
10.1. HOSPIRA, INC. 28
10.1.1. COMPANY OVERVIEW 28
10.1.2. SCOT ANALYSIS 28
10.1.3. PRODUCT BENCHMARKING 28
10.1.4. STRATEGIC INITIATIVES 28
10.2. MERCK KGAA 28
10.2.1. COMPANY OVERVIEW 28
10.2.2. SCOT ANALYSIS 28
10.2.3. PRODUCT BENCHMARKING 28
10.2.4. STRATEGIC INITIATIVES 28
10.3. CELLTRION, INC. 28
10.3.1. COMPANY OVERVIEW 28
10.3.2. SCOT ANALYSIS 28
10.3.3. PRODUCT BENCHMARKING 28
10.3.4. STRATEGIC INITIATIVES 28
10.4. MYLAN, INC. 28
10.4.1. COMPANY OVERVIEW 28
10.4.2. SCOT ANALYSIS 28
10.4.3. PRODUCT BENCHMARKING 28
10.4.4. STRATEGIC INITIATIVES 28
10.5. DR. REDDY'S LABORATORIES 28
10.5.1. COMPANY OVERVIEW 28
10.5.2. SCOT ANALYSIS 28
10.5.3. PRODUCT BENCHMARKING 28
10.5.4. STRATEGIC INITIATIVES 28
10.6. BIOCON LTD. 28
10.6.1. COMPANY OVERVIEW 28
10.6.2. SCOT ANALYSIS 29
10.6.3. PRODUCT BENCHMARKING 29
10.6.4. STRATEGIC INITIATIVES 29
10.7. AMGEN 29
10.7.1. COMPANY OVERVIEW 29
10.7.2. SCOT ANALYSIS 29
10.7.3. PRODUCT BENCHMARKING 29
10.7.4. STRATEGIC INITIATIVES 29
10.8. SANDOZ INTERNATIONAL GMBH 29
10.8.1. COMPANY OVERVIEW 29
10.8.2. SCOT ANALYSIS 29
10.8.3. PRODUCT BENCHMARKING 29
10.8.4. STRATEGIC INITIATIVES 29
10.9. TEVA PHARMACEUTICAL INDUSTRIES LTD. 29
10.9.1. COMPANY OVERVIEW 29
10.9.2. SCOT ANALYSIS 29
10.9.3. PRODUCT BENCHMARKING 29
10.9.4. STRATEGIC INITIATIVES 29
10.10. ROCHE DIAGNOSTICS 29
10.10.1. COMPANY OVERVIEW 29
10.10.2. SCOT ANALYSIS 29
10.10.3. PRODUCT BENCHMARKING 29
10.10.4. STRATEGIC INITIATIVES 29
10.11. STADA ARZNEIMITTEL AG 29
10.11.1. COMPANY OVERVIEW 29
10.11.2. SCOT ANALYSIS 29
10.11.3. PRODUCT BENCHMARKING 29
10.11.4. STRATEGIC INITIATIVES 29
10.12. RATIOPHARM GMBH 30
10.12.1. COMPANY OVERVIEW 30
10.12.2. SCOT ANALYSIS 30
10.12.3. PRODUCT BENCHMARKING 30
10.12.4. STRATEGIC INITIATIVES 30
10.13. INTAS PHARMACEUTICALS LTD. 30
10.13.1. COMPANY OVERVIEW 30
10.13.2. SCOT ANALYSIS 30
10.13.3. PRODUCT BENCHMARKING 30
10.13.4. STRATEGIC INITIATIVES 30
10.14. LG LIFE SCIENCES 30
10.14.1. COMPANY OVERVIEW 30
10.14.2. SCOT ANALYSIS 30
10.14.3. PRODUCT BENCHMARKING 30
10.14.4. STRATEGIC INITIATIVES 30
10.15. SYNTHON PHARMACEUTICALS, INC. 30
10.15.1. COMPANY OVERVIEW 30
10.15.2. SCOT ANALYSIS 30
10.15.3. PRODUCT BENCHMARKING 30
10.15.4. STRATEGIC INITIATIVES 30

TABLE 1 GLOBAL BIOSIMILARS MARKET BY PRODUCT TYPE 2012-2022 ($ BILLION) 31
TABLE 2 GLOBAL BIOSIMILARS MARKET BY RECOMBINANT PEPTIDES , 2012-2022 ($ BILLION) 31
TABLE 3 GLOBAL BIOSIMILARS RECOMBINANT PEPTIDES MARKET BY GLUCAGON , 2012-2022 ($ BILLION) 31
TABLE 4 GLOBAL BIOSIMILARS RECOMBINANT PEPTIDES MARKET BY CALCITONIN , 2012-2022 ($ BILLION) 31
TABLE 5 GLOBAL BIOSIMILARS MARKET BY GLYCOSYLATED PROTEINS, 2012-2022 ($ BILLION) 31
TABLE 6 GLOBAL BIOSIMILARS GLYCOSYLATED PROTEINS MARKET BY ERYTHROPOIETIN (EPO), 2012-2022 ($ BILLION) 31
TABLE 7 GLOBAL BIOSIMILARS GLYCOSYLATED PROTEINS MARKET BY FOLLITROPIN, 2012-2022 ($ BILLION) 31
TABLE 8 GLOBAL BIOSIMILARS GLYCOSYLATED PROTEINS MARKET BY MONOCLONAL ANTIBODIES (MABS) , 2012-2022 ($ BILLION) 31
TABLE 9 GLOBAL BIOSIMILARS MARKET BY RECOMBINANT NON- GLYCOSYLATED PROTEINS, 2012-2022 ($ BILLION) 31
TABLE 10 GLOBAL BIOSIMILARS RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET BY INTERFERONS, 2012-2022 ($ BILLION) 31
TABLE 11 GLOBAL BIOSIMILARS RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET BY RECOMBINANT HUMAN GROWTH HORMONE (RHGH) , 2012-2022 ($ BILLION) 31
TABLE 12 GLOBAL BIOSIMILARS RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET BY GRANULOCYTE COLONY-STIMULATING FACTOR (FILGRASTIM) , 2012-2022 ($ BILLION) 31
TABLE 13 GLOBAL BIOSIMILARS RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET BY INSULIN, 2012-2022 ($ BILLION) 31
TABLE 14 GLOBAL BIOSIMILARS MARKET BY APPLICATION 2012-2022 ($ BILLION) 31
TABLE 15 GLOBAL BIOSIMILARS MARKET BY BLOOD DISORDERS , 2012-2022 ($ BILLION) 31
TABLE 16 GLOBAL BIOSIMILARS MARKET BY CHRONIC AND AUTOIMMUNE DISEASES, 2012-2022 ($ BILLION) 31
TABLE 17 GLOBAL BIOSIMILARS MARKET BY ONCOLOGY, 2012-2022 ($ BILLION) 32
TABLE 18 GLOBAL BIOSIMILARS MARKET BY GROWTH HORMONE DEFICIENCY, 2012-2022 ($ BILLION) 32
TABLE 19 GLOBAL BIOSIMILARS MARKET BY INFECTIOUS DISEASES, 2012-2022 ($ BILLION) 32
TABLE 20 GLOBAL BIOSIMILARS MARKET BY OTHER APPLICATIONS, 2012-2022 ($ BILLION) 32
TABLE 21 GLOBAL BIOSIMILARS MARKET BY TECHNOLOGY 2012-2022 ($ BILLION) 32
TABLE 22 GLOBAL BIOSIMILARS MARKET BY NUCLEAR MAGNETIC RESONANCE (NMR) TECHNOLOGY, 2012-2022 ($ BILLION) 32
TABLE 23 GLOBAL BIOSIMILARS MARKET BY WESTERN BLOTTING, 2012-2022 ($ BILLION) 32
TABLE 24 GLOBAL BIOSIMILARS MARKET BY MONOCLONAL ANTIBODIES (MAB) TECHNOLOGY, 2012-2022 ($ BILLION) 32
TABLE 25 GLOBAL BIOSIMILARS MARKET BY ELECTROPHORESIS, 2012-2022 ($ BILLION) 32
TABLE 26 GLOBAL BIOSIMILARS MARKET BY CHROMATOGRAPHY, 2012-2022 ($ BILLION) 32
TABLE 27 GLOBAL BIOSIMILARS MARKET BY BIOASSAY, 2012-2022 ($ BILLION) 32
TABLE 28 GLOBAL BIOSIMILARS MARKET BY RECOMBINANT DNA TECHNOLOGY, 2012-2022 ($ BILLION) 32
TABLE 29 GLOBAL BIOSIMILARS MARKET BY MASS SPECTROMETRY, 2012-2022 ($ BILLION) 32
TABLE 30 GLOBAL BIOSIMILARS MARKET BY SERVICES 2012-2022 ($ BILLION) 32
TABLE 31 GLOBAL BIOSIMILARS MARKET BY CLINICAL TRIALS, 2012-2022 ($ BILLION) 32
TABLE 32 GLOBAL BIOSIMILARS MARKET BY CONTRACT RESEARCH & MANUFACTURING SERVICES (CRMS), 2012-2022 ($ BILLION) 32
TABLE 33 GLOBAL BIOSIMILARS MARKET, REGIONAL OUTLOOK 2012-2022 ($ BILLION) 32
TABLE 34 GLOBAL BIOSIMILARS MARKET BY REGION 2012-2022 ($ BILLION) 33
TABLE 35 NORTH AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 33
TABLE 36 NORTH AMERICA MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ BILLION) 33
TABLE 37 NORTH AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 33
TABLE 38 U.S. MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 33
TABLE 39 U.S. MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 33
TABLE 40 CANADA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 33
TABLE 41 CANADA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 33
TABLE 42 EUROPE MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 33
TABLE 43 EUROPE MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ BILLION) 33
TABLE 44 EUROPE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 33
TABLE 45 GERMANY MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 33
TABLE 46 GERMANY MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 33
TABLE 47 UK MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 33
TABLE 48 UK MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 33
TABLE 49 FRANCE MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 33
TABLE 50 FRANCE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 33
TABLE 51 SPAIN MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 34
TABLE 52 SPAIN MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 34
TABLE 53 RUSSIA MARKET ESTIMATES AND FORECAST2012-2022($BILLION) 34
TABLE 54 RUSSIA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022($BILLION) 34
TABLE 55 OTHERS MARKET ESTIMATES AND FORECAST2012-2022($BILLION) 34
TABLE 56 OTHERS MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022($BILLION) 34
TABLE 57 ASIA PACIFIC MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 34
TABLE 58 ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ BILLION) 34
TABLE 59 ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 34
TABLE 60 CHINA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 34
TABLE 61 CHINA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 34
TABLE 62 INDIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 34
TABLE 63 INDIA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 34
TABLE 64 JAPAN MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 34
TABLE 65 JAPAN MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($BILLION) 34
TABLE 66 SOUTH KOREA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 34
TABLE 67 SOUTH KOREA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($BILLION) 34
TABLE 68 OTHER MARKET ESTIMATES AND FORECASTS 2012-2022($BILLION) 35
TABLE 69 OTHER MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022($BILLION) 35
TABLE 70 MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 35
TABLE 71 MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 35
TABLE 72 LATIN AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 35
TABLE 73 LATIN AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 35
TABLE 74 BRAZIL MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 35
TABLE 75 BRAZIL MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 35

FIGURE 1 MARKET SHARE BY REGIONS 33
FIGURE 2 UNITED STATES MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 33
FIGURE 3 CANADA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 33
FIGURE 4 EUROPE MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 33
FIGURE 5 GERMANY MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 33
FIGURE 6 UK MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 33
FIGURE 7 FRANCE MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 33
FIGURE 8 SPAIN MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 33
FIGURE 9 APAC MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 34
FIGURE 10 CHINA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 34
FIGURE 11 INDIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 34
FIGURE 12 JAPAN MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 34
FIGURE 13 SPAIN MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 34
FIGURE 14 MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 34
FIGURE 15 LATIN AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 34
FIGURE 16 BRAZIL AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 34

Choose License


Contact Information

: 24/7 Research Support

: sales@briskinsights.com

: +448081890034 (UK)